Literature DB >> 16735030

Low cerebrospinal fluid glutamate and glycine in refractory affective disorder.

Mark A Frye1, Guochuan E Tsai, Teresa Huggins, Joseph T Coyle, Robert M Post.   

Abstract

BACKGROUND: Glutamatergic dysregulation has been documented in schizophrenia but has received less systematic study in affective illness.
METHODS: Cerebrospinal fluid (CSF) levels of the excitatory amino acids glutamate (Glu) and aspartate (Asp) and the N-methyl-D-aspartate (NMDA) receptor modulator, glycine (GLY) were measured by high performance liquid chromatography in 32 patients with refractory affective disorder (16 female/16 male, 12 bipolar I, 12 bipolar II, and 8 unipolar) and in 14 age-matched controls.
RESULTS: There was a significant reduction in CSF glutamate and glycine in patients versus controls. A diagnosis by sex interaction was present for CSF glycine with lower levels in female patients compared to female controls. Levels of the excitatory amino acids were highly inter-correlated in patients, but not in controls. In patients studied after 6 weeks of lamotrigine, there was a trend for CSF glutamate levels to increase.
CONCLUSIONS: These data suggest that in patients with refractory affective disorder, excitatory amino acids are dysregulated, as exemplified both by the decreased CSF glutamate and glycine and their high intercorrelation compared to controls. Further controlled study of glutamatergic dysregulation and its relationship to the pathophysiology of affective disorders and potential mechanism of action of mood stabilizers appears indicated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735030     DOI: 10.1016/j.biopsych.2006.01.024

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  37 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

3.  Genome-wide association study of NMDA receptor coagonists in human cerebrospinal fluid and plasma.

Authors:  J J Luykx; S C Bakker; W F Visser; N Verhoeven-Duif; J E Buizer-Voskamp; J M den Heijer; M P M Boks; J H Sul; E Eskin; A P Ori; R M Cantor; J Vorstman; E Strengman; J DeYoung; T H Kappen; E Pariama; E P A van Dongen; P Borgdorff; P Bruins; T J de Koning; R S Kahn; R A Ophoff
Journal:  Mol Psychiatry       Date:  2015-02-10       Impact factor: 15.992

4.  Metabolomic differences in heart failure patients with and without major depression.

Authors:  David C Steffens; K Ranga R Krishnan; Edward D Karoly; Matthew W Mitchell; Christopher M O'Connor; Rima Kaddurah-Daouk
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-01-25       Impact factor: 2.680

Review 5.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 6.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

7.  Modulation of DNA Methylation and Gene Expression in Rodent Cortical Neuroplasticity Pathways Exerts Rapid Antidepressant-Like Effects.

Authors:  Amanda J Sales; Izaque S Maciel; Angélica C D R Suavinha; Sâmia R L Joca
Journal:  Mol Neurobiol       Date:  2020-10-06       Impact factor: 5.590

8.  Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.

Authors:  Sonja Horstmann; Susanne Lucae; Andreas Menke; Johannes M Hennings; Marcus Ising; Darina Roeske; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

9.  Correlations between plasma levels of amino acids and nonmotor symptoms in Parkinson's disease.

Authors:  Qing Tong; Qinrong Xu; Qiang Xia; Yongsheng Yuan; Li Zhang; Hongbin Sun; Han Shan; Kezhong Zhang
Journal:  J Neural Transm (Vienna)       Date:  2014-07-25       Impact factor: 3.575

Review 10.  Ketamine and the next generation of antidepressants with a rapid onset of action.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy Diazgranados; Carlos A Zarate
Journal:  Pharmacol Ther       Date:  2009-05-03       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.